Philip Gibbs, MD
Internal Medicine · Aberdeen, WANPI 1548283617
Payments from drug & device makers
Across 174 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$745
- Johnson & Johnson$463
- Novartis$382
- Pfizer$250
- Amgen$247
- Boehringer Ingelheim$159
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,35297%
- Education$1203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $745 |
| Johnson & Johnson | 19 | $463 |
| Novartis | 21 | $382 |
| Pfizer | 12 | $250 |
| Amgen | 9 | $247 |
| Boehringer Ingelheim | 13 | $159 |
| Bayer | 8 | $149 |
| AbbVie | 6 | $139 |
| CMP Pharma, Inc. | 6 | $97 |
| Kyowa Kirin, Inc. | 4 | $96 |
| Kowa Pharmaceuticals America, Inc. | 6 | $93 |
| Phathom Pharmaceuticals, Inc. | 6 | $90 |
| Mylan Specialty L.p. | 4 | $71 |
| Merck | 4 | $61 |
| Esperion Therapeutics, Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Scpharmaceuticals Inc. | 1 | $14 |
How this compares
$3,471 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 471 | $323,467 |
| XareltoRivaroxaban | 118 | $88,289 |
| Taltz AutoinjectorIxekizumab | 12 | $77,586 |
| FarxigaDapagliflozin Propanediol | 67 | $65,295 |
| JanuviaSitagliptin Phosphate | 76 | $62,270 |
| TrulicityDulaglutide | 45 | $49,315 |
| MounjaroTirzepatide | 35 | $36,514 |
| OzempicSemaglutide | 21 | $31,268 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $18,850 |
| JardianceEmpagliflozin | 27 | $17,917 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $15,953 |
| EntrestoSacubitril/Valsartan | 22 | $14,335 |
| Atrovent HfaIpratropium Bromide | 19 | $13,555 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,438 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $250 | $323,467471 claims |
| Johnson & JohnsonXarelto | $463 | $88,289118 claims |
| AstraZenecaFarxiga, Brilinta | $745 | $73,57588 claims |
| MerckJanuvia, Janumet | $61 | $71,322102 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $159 | $33,87159 claims |
| NovartisEntresto | $382 | $14,33522 claims |
| BayerKerendia | $149 | $6,59611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $21 | $5,17611 claims |
| Esperion Therapeutics, Inc.Nexlizet | $59 | $3,96811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Aberdeen
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
- Shelly KhuranaLynnwood$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.